Investors
Shareholder Information
Incanthera plc's shares are traded on the Access Segment of AQSE Exchange Growth Market, Updated as of 23 April 2024.
Symbol: INC
| ISIN |
GB00BGL7YW15 |
| LEI code |
2138002HEV4UFBOEXQ97 |
There are no restrictions on the transfer of AQSE Securities.
The main country of operation is United Kingdom. Incorporated and registered in England and Wales with registered number 11026926.
Incanthera plc is subject to the City Code on Takeovers and Mergers.
Shareholder Analysis
| No. of shares in issue: |
99,276,547
|
| Warrants outstanding: |
12,131,516 |
| Options outstanding: |
9,175,000 |
| Fully diluted: |
120,583,063
|
| Percentage of Shares in public hands: |
43.53% |
| Percentage of Shares not in public hands: |
56.47% |
Major Shareholdings
| Shareholder |
Number of shares held |
% of issued share capital |
|
Tyndall Investment Management
|
16,238,782
|
16.36%
|
|
NWF (Biomedical) LP
|
16,164,540
|
16.28%
|
|
University of Bradford
|
10,349,183
|
10.42%
|
|
Immupharma Plc
|
9,904,319
|
9.98%
|
|
The Bank Of New York (Nominees) Limited
|
4,152,311
|
4.18%
|
|
Mr Tim McCarthy
|
3,931,646
|
3.96%
|
|
Mr Simon Ward
|
3,064,199
|
3.09%
|
Contact:
Head of Communications & Company Secretary
Suzanne Brocks
Suzanne.brocks@incanthera.com